These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 15619388

  • 1. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease.
    Warnholtz A, Ostad MA, Heitzer T, Goldmann BU, Nowak G, Munzel T.
    Am J Cardiol; 2005 Jan 01; 95(1):20-3. PubMed ID: 15619388
    [Abstract] [Full Text] [Related]

  • 2. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
    Akbulut M, Ozbay Y, Gundogdu O, Dagli N, Durukan P, Ilkay E, Arslan N.
    Curr Med Res Opin; 2004 Nov 01; 20(11):1759-67. PubMed ID: 15537476
    [Abstract] [Full Text] [Related]

  • 3. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S, Ambrosini V, Marzocchi A, Tolaro S, Petronio AS, Galassi AR, Bongo AS, Gaglione A, Bolognese L, IDEA Survey Investigators, Italian Society of Invasive Cardiology.
    Ital Heart J; 2005 Feb 01; 6(2):106-18. PubMed ID: 15819503
    [Abstract] [Full Text] [Related]

  • 4. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, Hao GZ, Li SQ, Jiang YF, Geng W.
    Chin Med J (Engl); 2008 Mar 20; 121(6):522-7. PubMed ID: 18364139
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased brachial-ankle pulse wave velocity is associated with impaired endothelial function in patients with coronary artery disease.
    Liu DH, Wang Y, Liao XX, Xu MG, Wang JM, Yang Z, Chen L, Lü MD, Lu K, Tao J.
    Chin Med J (Engl); 2006 Nov 20; 119(22):1866-70. PubMed ID: 17134584
    [Abstract] [Full Text] [Related]

  • 10. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.
    Coron Artery Dis; 2008 Jun 20; 19(4):271-7. PubMed ID: 18480672
    [Abstract] [Full Text] [Related]

  • 11. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ.
    Coron Artery Dis; 2009 Jun 20; 20(4):267-73. PubMed ID: 19440065
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, Giannitsis E.
    Thromb Haemost; 2008 Oct 20; 100(4):648-54. PubMed ID: 18841288
    [Abstract] [Full Text] [Related]

  • 15. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S, Mezyński G, Kralisz P, Prokopczuk P, Nowak K, Kochman W, Zuk J, Bachórzewska-Gajewska H, Sawicki Z, Poniatowski B, Korecki J, Musiał WJ.
    Kardiol Pol; 2006 Aug 20; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [Abstract] [Full Text] [Related]

  • 16. Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.
    Steen H, Lehrke S, Wiegand UK, Merten C, Schuster L, Richardt G, Kulke C, Gehl HB, Lima JA, Katus HA, Giannitsis E.
    Am Heart J; 2005 Mar 20; 149(3):564. PubMed ID: 15864217
    [Abstract] [Full Text] [Related]

  • 17. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J, Gurm HS, Rajagopal V, Fathi R, Bavry AA, Brener SJ, Lincoff AM, Ellis SG, Bhatt DL.
    Am J Cardiol; 2006 Oct 01; 98(7):906-10. PubMed ID: 16996871
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial.
    Lavi S, Thorpe K, Luca MC, Liuni A, Floras J, Horlick EM, Ing D, Osten MD, Overgaard CB, Lan J, Parker JD, Cantor WJ, Džavík V.
    Can J Cardiol; 2012 Oct 01; 28(2):215-21. PubMed ID: 22281412
    [Abstract] [Full Text] [Related]

  • 19. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, GRACE Investigators.
    Am Heart J; 2007 Jun 01; 153(6):960-9. PubMed ID: 17540196
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.